SEC Form 4 · accession 0001104659-16-137660
MARINUS PHARMACEUTICALS INC · MRNS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Christopher Michael Cashman
Officer — Chairman and CEO · Director
Period of report
Aug 3, 2016
Accepted (ET)
Aug 5, 2016 · 5:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001267813
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $1.50 | Aug 3, 2016 | A | 130,900 | A | — | Aug 3, 2026 | Common Stock | 130,900 | 130,900 | D |
| Restricted stockF2,F3 | — | Aug 3, 2016 | A | 56,100 | A | — | Aug 3, 2026 | Common Stock | 56,100 | 56,100 | D |
Explanation of responses
- F1Options to purchase shares of common stock vest in 24 equal monthly installments commencing 09/01/2017.
- F2Each share of restricted stock represents the right to receive, at settlement, one share of common stock.
- F3All shares of restricted stock vest on 8/3/17.